rais strong symdeko launch
gate
beat rais
report non-gaap ep top consensu total cystic
fibrosi cf product revenu handili beat consensu non-
 sg expens in-lin expect
respect earn beat driven strong launch symdeko us
result rais cf product revenu guidanc
reiter buy vrtx indisput leadership posit cf
symdeko launch continu impress
recent approv symdeko post sale first full quarter top
consensu beat driven uptak nave orkambi-discontinu
patient well orkambi switch due faster-than-expect switch
surpris miss orkambi sale vs consensu total
orkambi/symdeko sale consensu kalydeco sale
also beat consensu overal encourag growth cf
franchis driven impress symdeko launch see trajectori continu
homozyg cftr market yet fulli penetr hand
continu monitor progress eu reimburs orkambi to-be-approv
symdeko portfolio reimburs strategi shape given strong
launch symdeko rais revenu guidanc increas sale estim
howev updat revenu beyond later-than-
expect eu reimburs result ep chang
file tripl combin later
expect complet enrol four phase studi
plan file fda approv later addit
symdeko data pediatr patient expect initi beta
thalassemia expect later year work fda address clinic
hold regard ind sickl cell diseas expect expand
pipelin progress intern program well extern partnership
and/or acquisit cash balanc coupl fast grow cash flow
afford financi wherewith scout opportun
net dbt
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
vertex biopharmaceut compani focus
discoveri develop market new
therapi treatment cystic fibrosi
posit view believ
remain leader cystic fibrosi treatment
multipl posit readout next-gener cf
tripl combin allow penetr
price object base probability-adjust npv analysi
cash flow use wacc deriv follow valu
kalydeco orkambi tez/iva tripl combin homozyg
patient tripl combin heterozyg patient
inclus net cash
downsid risk price object slower expect launch orkambi
lower price increment price pressur failur phase trial tripl
combin addit pipelin setback upsid risk quicker
expect uptak orkambi better expect pricing/compli orkambi
quicker develop tripl combo heterozyg patient
ying huang herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
